{"result": "(\"entity\"<|>TUMORES NEUROENDOCRINOS<|>EVENT<|>Neuroendocrine tumors are a type of tumor that can affect hormone production and are discussed in the context of endocrine disorders.)\n##\n(\"entity\"<|>RALOXIFENO<|>EVENT<|>Raloxifene is a medication that acts as an estrogen agonist in bone and is used to reduce the risk of breast cancer and osteoporosis in postmenopausal women.)\n##\n(\"entity\"<|>TAMOXIFENO<|>EVENT<|>Tamoxifen is a medication that blocks estrogen's effects in breast tissue and is used in the treatment of breast cancer.)\n##\n(\"entity\"<|>RANELATO DE ESTRONCIO<|>EVENT<|>Strontium ranelate is a medication that stimulates bone formation and is used in the treatment of osteoporosis.)\n##\n(\"entity\"<|>OSTEOBLASTOS<|>EVENT<|>Osteoblasts are cells responsible for bone formation, and their function is crucial in the context of osteoporosis.)\n##\n(\"entity\"<|>OSTEOCITOS<|>EVENT<|>Osteocytes are mature bone cells that play a role in maintaining bone tissue and are affected by glucocorticoid treatment.)\n##\n(\"entity\"<|>DMO VERTEBRAL<|>EVENT<|>Vertebral bone mineral density (BMD) is a key indicator of osteoporosis and is used to assess fracture risk.)\n##\n(\"entity\"<|>PTH<|>EVENT<|>Parathyroid hormone (PTH) is involved in calcium regulation and bone metabolism, and its dynamics are altered by glucocorticoids.)\n##\n(\"entity\"<|>IGF-1<|>EVENT<|>Insulin-like growth factor 1 (IGF-1) is a hormone that plays a role in bone growth and metabolism, and its expression is suppressed by glucocorticoids.)\n##\n(\"relationship\"<|>RALOXIFENO<|>OSTEOPOROSIS<|>Raloxifene is used to reduce the risk of osteoporosis in postmenopausal women<|>8)\n##\n(\"relationship\"<|>TAMOXIFENO<|>OSTEOPOROSIS<|>Tamoxifen is used in the treatment of breast cancer and has implications for bone health in women<|>7)\n##\n(\"relationship\"<|>RANELATO DE ESTRONCIO<|>OSTEOPOROSIS<|>Strontium ranelate is used to stimulate bone formation and reduce fracture risk in osteoporosis<|>8)\n##\n(\"relationship\"<|>OSTEOBLASTOS<|>OSTEOPOROSIS<|>Osteoblasts are critical for bone formation, and their function is impaired in osteoporosis<|>9)\n##\n(\"relationship\"<|>OSTEOCITOS<|>OSTEOPOROSIS<|>Osteocytes are involved in bone maintenance, and their apoptosis is increased in osteoporosis<|>8)\n##\n(\"relationship\"<|>PTH<|>OSTEOPOROSIS<|>PTH dynamics are altered in osteoporosis, affecting calcium homeostasis and bone metabolism<|>7)\n##\n(\"relationship\"<|>IGF-1<|>OSTEOPOROSIS<|>IGF-1 is important for bone growth, and its suppression by glucocorticoids contributes to osteoporosis<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: geno, como el tamoxifeno y el raloxifeno bloquean las acciones del estrógeno en la mama, pero actúan como agonistas de\n---\nMETABOLISMO FOSFOCÁLCICO, TUMORES NEUROENDOCRINOS Y MEN 7\n\nestrógeno en el hueso. Ambos fármacos se han asociado a una reducción de cáncer de mama. La concentración de colesterol en lipoproteínas de densidad baja disminuye también en pacientes que reciben este tratamiento.\n\nEl raloxifeno aumenta ligeramente la DMO vertebral y baja un 40% el riesgo de fractura vertebral, pero no modifica el riesgo de fractura no vertebral.\n\nEl ranelato de estroncio estimula la absorción ósea de calcio e inhibe la resorción ósea. En mujeres posmenopáusicas con enfermedad confirmada, disminuyó un 40% el riesgo de fracturas vertebrales. Datos recientes indican un aumento de los episodios cardiovasculares en mujeres tratadas con estroncio.\n\nLos osteoclastos tienen receptores de calcitonina y la calcitonina puede inhibir rápidamente la resorción ósea. En mujeres con osteoporosis posmenopáusica, la calcitonina nasal en dosis de 200 UI/día bajó una tercera parte la incidencia de fractura vertebral.\n\nReferencias:\n- Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n- Rosen HN. The use of bisphosphonates in postmenopausal women with osteoporosis. Rosen CJ, Schmader KE, eds. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 11 de junio de 2019).\n- Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Rosen CJ, Schmader KE, eds. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 11 de junio de 2019).\n\n## En la osteoporosis secundaria a glucocorticoides, indique cuál de las siguientes afirmaciones es falsa:\n\nA. Existe una inhibición de la absorción del calcio por alteración de la producción de 1,25(OH)2D3.\nB. Los glucocorticoides suprimen la expresión de IGF-1 en las células óseas.\nC. El hueso más afectado es el trabecular.\nD. Los marcadores de resorción ósea son muy útiles en el seguimiento de estos pacientes.\n\nCOMENTARIO\n\nEl hueso trabecular es el más afectado y la DMO vertebral es el indicador más sensible de la pérdida ósea. Los marcadores de recambio óseo no son útiles en el tratamiento de estos pacientes (opción D falsa: respuesta correcta).\n\nLos glucocorticoides disminuyen la absorción intestinal de calcio por alteración de la producción de la 1,25(OH)2D3 y al disminuir la expresión de los canales de calcio en el duodeno. Los glucocorticoides aumentan la excreción renal de calcio al disminuir la reabsorción de calcio. Ambas acciones dan como resultado un aumento de la PTH sérica y, posteriormente, un aumento de la resorción ósea.\n\nCon el uso a largo plazo, el efecto predominante de los glucocorticoides en el esqueleto es la reducción de la formación de hueso. La disminución de la formación ósea está mediada por la inhibición directa de la proliferación y diferenciación de los osteoblastos y por un au-\n\nmento en las tasas de apoptosis de los osteoblastos y osteocitos maduros. Esta apoptosis también puede explicar la tendencia de los glucocorticoides a causar osteonecrosis.\n\nAdemás, los glucocorticoides alteran la dinámica secretora de la PTH (reducen la secreción tónica y aumentan la cantidad liberada como pulsos), antagonizan la acción anabólica de la PTH e inhiben la producción del IGF-1 y testosterona. La reducción en la formación ósea se asocia con una disminución en la tasa de aposición de minerales y en los marcadores bioquímicos de formación ósea en suero y orina.\n\nReferencias:\n- Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n- Rosen HN. Clinical features and evaluation of glucocorticoid-induced osteoporosis. Rosen CJ, ed. UptoDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 11 de junio de 2019).\n- Rosen HN, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. Rosen CJ, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.upt\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>MELMED S<|>PERSON<|>Melmed S is an author of the Williams Textbook of Endocrinology, which discusses various aspects of endocrinology and osteoporosis treatment.)\n##\n(\"entity\"<|>POLONSKY KS<|>PERSON<|>Polonsky KS is a co-author of the Williams Textbook of Endocrinology, contributing to the understanding of hormonal regulation and osteoporosis.)\n##\n(\"entity\"<|>REED LARSEN P<|>PERSON<|>Reed Larsen P is a co-author of the Williams Textbook of Endocrinology, providing insights into endocrine disorders and their management.)\n##\n(\"entity\"<|>KRONENBERG HM<|>PERSON<|>Kronenberg HM is a co-author of the Williams Textbook of Endocrinology, focusing on hormonal influences on bone metabolism.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc. is a clinical decision support resource that provides evidence-based information for healthcare professionals, including topics on osteoporosis management.)\n##\n(\"entity\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>ORGANIZATION<|>The Williams Textbook of Endocrinology is a comprehensive reference on endocrinology, covering various diseases and treatments, including osteoporosis.)\n##\n(\"entity\"<|>OSTEOPOROSIS<|>EVENT<|>Osteoporosis is a medical condition characterized by weakened bones, increasing the risk of fractures, particularly in postmenopausal women and those on glucocorticoids.)\n##\n(\"entity\"<|>GLUCOCORTICOIDS<|>EVENT<|>Glucocorticoids are a class of steroid hormones that can lead to osteoporosis when used long-term, affecting calcium absorption and bone formation.)\n##\n(\"entity\"<|>CALCITONINA<|>EVENT<|>Calcitonin is a hormone that can inhibit bone resorption and is used in the treatment of osteoporosis to reduce fracture risk.)\n##\n(\"entity\"<|>BISPHOSPHONATES<|>EVENT<|>Bisphosphonates are medications used to prevent the loss of bone density in osteoporosis patients.)\n##\n(\"relationship\"<|>MELMED S<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Melmed S is a co-author of the Williams Textbook of Endocrinology, contributing to its content on osteoporosis<|>8)\n##\n(\"relationship\"<|>POLONSKY KS<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Polonsky KS is a co-author of the Williams Textbook of Endocrinology, contributing to its content on osteoporosis<|>8)\n##\n(\"relationship\"<|>REED LARSEN P<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Reed Larsen P is a co-author of the Williams Textbook of Endocrinology, contributing to its content on osteoporosis<|>8)\n##\n(\"relationship\"<|>KRONENBERG HM<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Kronenberg HM is a co-author of the Williams Textbook of Endocrinology, contributing to its content on osteoporosis<|>8)\n##\n(\"relationship\"<|>UPTODATE INC<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>UpToDate Inc. provides clinical information that complements the content of the Williams Textbook of Endocrinology<|>6)\n##\n(\"relationship\"<|>GLUCOCORTICOIDS<|>OSTEOPOROSIS<|>Glucocorticoids are known to cause osteoporosis as a side effect of long-term use<|>9)\n##\n(\"relationship\"<|>BISPHOSPHONATES<|>OSTEOPOROSIS<|>Bisphosphonates are used as a treatment to prevent and manage osteoporosis<|>8)\n##\n(\"relationship\"<|>CALCITONINA<|>OSTEOPOROSIS<|>Calcitonin is used in the treatment of osteoporosis to help reduce the risk of fractures<|>7)\n<|COMPLETE|>"}]}